close
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Mucosal immunity and vaccines

Nature Medicine volume 11, pages S45–S53 (2005) Cite this article

Save article
View saved research

Abstract

There is currently great interest in developing mucosal vaccines against a variety of microbial pathogens. Mucosally induced tolerance also seems to be a promising form of immunomodulation for treating certain autoimmune diseases and allergies. Here we review the properties of the mucosal immune system and discuss advances in the development of mucosal vaccines for protection against infections and for treatment of various inflammatory disorders.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Expression of mucosal IgA immune responses after different routes of vaccination.
BERJAYA
Figure 2: Different approaches toward development of mucosal adjuvants based on detoxified cholera toxin (CT) or E. coli heat-labile enterotoxin (LT).
BERJAYA

Similar content being viewed by others

References

  1. Mestecky, J. et al. (eds). Mucosal Immunology 3rd edn. (Academic Press, San Diego, 2005).

    Google Scholar 

  2. Mowat, A.M. Anatomical basis of tolerance and immunity to intestinal antigens. Nat. Rev. Immunol. 3, 331–341 (2003).

    Article  CAS  PubMed  Google Scholar 

  3. Kiyono, H. & Fukuyama, S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat. Rev. Immunol. 4, 699–710 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ishikawa, H., Saito, H., Suzuki, K., Oida, T. & Kanamori, Y. New gut associated lymphoid tissue “cryptopatches” breed murine intestinal intraepithelial T cell precursors. Immunol. Res. 20, 243–250 (1999).

    Article  CAS  PubMed  Google Scholar 

  5. Guy-Grand, D. et al. Extrathymic T cell lymphopoiesis: ontogeny and contribution to gut intraepithelial lymphocytes in athymic and euthymic mice. J. Exp. Med. 197, 333–341 (2003).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bilsborough, J. & Viney, J.L. Gastrointestinal dendritic cells play a role in immunity, tolerance, and disease. Gastroenterology 127, 300–309 (2004).

    Article  CAS  PubMed  Google Scholar 

  7. Iwasaki, A. & Kelsall, B.L. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J. Exp. Med. 190, 229–239 (1999).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. & Medzhitov, R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118, 229–241 (2004).

    Article  CAS  PubMed  Google Scholar 

  9. Kunkel, E.J. & Butcher, E.C. Plasma-cell homing. Nat. Rev. Immunol. 3, 822–829 (2003).

    Article  CAS  PubMed  Google Scholar 

  10. Campbell, D.J., Debes, G.F., Johnston, B., Wilson, E. & Butcher, E.C. Targeting T cell responses by selective chemokine receptor expression. Semin. Immunol. 15, 277–286 (2003).

    Article  CAS  PubMed  Google Scholar 

  11. Stagg, A.J., Kamm, M.A. & Knight, S.C. Intestinal dendritic cells increase T cell expression of α4β7 integrin. Eur. J. Immunol. 32, 1445–1454 (2002).

    Article  CAS  PubMed  Google Scholar 

  12. Mora, J.R. et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 424, 88–93 (2003).

    Article  CAS  PubMed  Google Scholar 

  13. Iwata, M. et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity 21, 527–538 (2004).

    Article  CAS  PubMed  Google Scholar 

  14. Quiding, M. et al. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses, gamma-interferon production, and evokes local immunological memory. J. Clin. Invest. 88, 143–148 (1991).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Eriksson, K. et al. Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination. Infect. Immun. 66, 5889–5896 (1998).

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Kozlowski, P.A., Cu-Uvin, S., Neutra, M.R. & Flanigan, T.P. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect. Immun. 65, 1387–1394 (1997).

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Jertborn, M., Nordström, I., Kilander, A., Czerkinsky, C. & Holmgren, J. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect. Immun. 69, 4125–4128 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Johansson, E.L., Bergquist, C., Edebo, A., Johansson, C. & Svennerholm, A.-M. Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine 22, 984–990 (2004).

    Article  CAS  PubMed  Google Scholar 

  19. Johansson, E.-L., Wassén, L., Holmgren, J., Jertborn, M. & Rudin, A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect. Immun. 69, 7481–7486 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Nardelli-Haefliger, D. et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J. Natl. Cancer Inst. 95, 1128–1137 (2003).

    Article  PubMed  Google Scholar 

  21. Gockel, C.M., Bao, S. & Beagley, K.W. Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract. Mol. Immunol. 37, 537–544 (2000).

    Article  CAS  PubMed  Google Scholar 

  22. Yuan, Q. & Walker, W.A. Innate immunity of the gut: mucosal defense in health and disease. J. Pediatr. Gastroenterol. Nutr. 38, 463–473 (2004).

    Article  CAS  PubMed  Google Scholar 

  23. Lycke, N., Eriksen, L. & Holmgren, J. Protection against cholera toxin after oral immunization is thymus-dependent and associated with intestinal production of neutralizing IgA antitoxin. Scand. J. Immunol. 25, 413–419 (1987).

    Article  CAS  PubMed  Google Scholar 

  24. Hornquist, C.E., Ekman, L., Grdic, K.D., Schon, K. & Lycke, N.Y. Paradoxical IgA immunity in CD4-deficient mice. Lack of cholera toxin-specific protective immunity despite normal gut mucosal IgA differentiation. J. Immunol. 155, 2877–2887 (1995).

    CAS  PubMed  Google Scholar 

  25. Macpherson, A.J. et al. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 288, 2222–2226 (2000).

    Article  CAS  PubMed  Google Scholar 

  26. Stoel, M. et al. Restricted IgA repertoire in both B-1 and B-2 cell-derived gut plasmablasts. J. Immunol. 174, 1046–1054 (2005).

    Article  CAS  PubMed  Google Scholar 

  27. Goodrich, M.E. & McGee, D.W. Regulation of mucosal B cell immunoglobulin secretion by intestinal epithelial cell-derived cytokines. Cytokine 10, 948–955 (1998).

    Article  CAS  PubMed  Google Scholar 

  28. Asano, T. et al. Molecular analysis of B cell differentiation in selective or partial IgA defiency. Clin. Exp. Immunol. 136, 284–290 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Klavinskis, L.S. et al. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. J. Immunol. 157, 2521–2527 (1996).

    CAS  PubMed  Google Scholar 

  30. Staats, H.F. et al. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J. Immunol. 167, 5386–5394 (2001).

    Article  CAS  PubMed  Google Scholar 

  31. Belyakov, I.M., Hammond, S.A., Ahlers, J.D., Glenn, G.M. & Berzofsky, J.A. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest. 113, 998–1007 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Franco, M.A. & Greenberg, H.B. Role of B cells and cytotoxic T lymphocytes in clearance of and immunity to rotavirus infection in mice. J. Virol. 69, 7800–7806 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Bender, B.S., Croghan, T., Zhang, L. & Small, P.A. Jr. Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J. Exp. Med. 175, 1143–1145 (1992).

    Article  CAS  PubMed  Google Scholar 

  34. Buzoni-Gatel, D., Lepage, A.C., Dimier-Poisson, I.H., Bout, D.T. & Kasper, L.H. Adoptive transfer of gut intraepithelial lymphocytes protects against murine infection with Toxoplasma gondii. J. Immunol. 158, 5883–5889 (1997).

    CAS  PubMed  Google Scholar 

  35. Bowen, J.C., Nair, S.K., Reddy, R. & Rouse, B.T. Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens. Immunology 81, 338–342 (1994).

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Simmons, C.P. et al. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses. J. Immunol. 166, 1106–1113 (2001).

    Article  CAS  PubMed  Google Scholar 

  37. Johansson, M., Schön, K., Ward, M. & Lycke, N. Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response. Infect. Immun. 65, 1032–1044 (1997).

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Ermak, T.H. et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J. Exp. Med. 188, 2277–2288 (1998).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Harandi, A.M., Svennerholm, B., Holmgren, J. & Eriksson, K. Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity. J. Virol. 75, 6705–6709 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Wu, H.Y. & Weiner, H.L. Oral tolerance. Immunol. Res. 28, 265–284 (2003).

    Article  PubMed  Google Scholar 

  41. Whitacre, C.C., Gienapp, I.E., Orosz, C.G. & Bitar, D.M. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J. Immunol. 147, 2155–2163 (1991).

    CAS  PubMed  Google Scholar 

  42. Chen, Y. et al. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 376, 177–180 (1995).

    Article  CAS  PubMed  Google Scholar 

  43. Ngan, J. & Kind, L.S. Suppressor T cells for IgE and IgG in Peyer's patches of mice made tolerant by the oral administration of ovalbumin. J. Immunol. 120, 861–865 (1978).

    CAS  PubMed  Google Scholar 

  44. Polanski, M., Melican, N.S., Zhang, J. & Weiner, H.L. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. J. Autoimmun. 10, 339–346 (1997).

    Article  CAS  PubMed  Google Scholar 

  45. Groux, H. et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737–742 (1997).

    Article  CAS  PubMed  Google Scholar 

  46. Chen, Y., Kuchroo, V.K., Inobe, J., Hafler, D.A. & Weiner, H.L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265, 1237–1240 (1994).

    Article  CAS  PubMed  Google Scholar 

  47. Thornton, A.M. & Shevach, E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188, 287–296 (1998).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151–1164 (1995).

    CAS  PubMed  Google Scholar 

  49. Klein, L., Khazaie, K. & von Boehmer, H. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc. Natl Acad. Sci. USA 100, 8886–8891 (2003).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Walker, L.S., Chodos, A., Eggena, M., Dooms, H. & Abbas, A.K. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J. Exp. Med. 198, 249–258 (2003).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Stassen, M. et al. Human CD25+ regulatory T cells: two subsets defined by the integrins α4β7 or α4β1 confer distinct suppressive properties upon CD4+ T helper cells. Eur. J. Immunol. 34, 1303–1311 (2004).

    Article  CAS  PubMed  Google Scholar 

  52. Huang, C.T. et al. Role of LAG-3 in regulatory T cells. Immunity 21, 503–513 (2004).

    Article  CAS  PubMed  Google Scholar 

  53. McMenamin, C., Pimm, C., McKersey, M. & Holt, P.G. Regulation of IgE responses to inhaled antigen in mice by antigen-specific γδ T cells. Science 265, 1869–1871 (1994).

    Article  CAS  PubMed  Google Scholar 

  54. Hanninen, A. & Harrison, L.C. γδ T cells as mediators of mucosal tolerance: the autoimmune diabetes model. Immunol. Rev. 173, 109–119 (2000).

    Article  CAS  PubMed  Google Scholar 

  55. Crispe, I.N. Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 3, 51–62 (2003).

    Article  CAS  PubMed  Google Scholar 

  56. Roelofs-Haarhuis, K., Wu, X. & Gleichmann, E. Oral tolerance to nickel requires CD4+ invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells. J. Immunol. 173, 1043–1050 (2004).

    Article  CAS  PubMed  Google Scholar 

  57. Akbari, O., DeKruyff, R.H. & Umetsu, D.T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol. 2, 725–731 (2001).

    Article  CAS  PubMed  Google Scholar 

  58. Zhaori, G., Sun, M. & Ogra, P.L. Characteristics of the immune response to poliovirus virion polypeptides after immunization with live or inactivated polio vaccines. J. Infect. Dis. 158, 160–165 (1988).

    Article  CAS  PubMed  Google Scholar 

  59. World Health Organization. Cholera vaccines. WHO position paper. Wkly. Epidemiol. Rec. 76, 117–124 (2001).

  60. Holmgren, J. & Bergquist, C. Oral B subunit killed whole-cell cholera vaccines. in New Generation Vaccines 3rd edn. (ed. Levine, M.M. et al.) 499–510 (Marcel Dekker, New York, 2004).

    Google Scholar 

  61. Lucas, M. et al. High-level effectiveness of a mass oral cholera vaccination in Beira, Mozambique. N. Engl. J. Med. 352, 757–767 (2005).

    Article  CAS  PubMed  Google Scholar 

  62. Ali, M. et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh. Lancet (in the press).

  63. Trach, D.D. et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349, 231–235 (1997).

    Article  CAS  PubMed  Google Scholar 

  64. Levine, M.M. & Kaper, J.B. Live oral cholera vaccine: from principle to product. Bull. Inst. Pasteur 93, 243–253 (1995).

    Article  Google Scholar 

  65. Richie, E. et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 18, 2399–2410 (2000).

    Article  CAS  PubMed  Google Scholar 

  66. Acharya, I.L. et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N. Engl. J. Med. 317, 1101–1104 (1987).

    Article  CAS  PubMed  Google Scholar 

  67. Klugman, K. et al. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14, 435–438 (1996).

    Article  CAS  PubMed  Google Scholar 

  68. Yang, H.H. et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in Southwestern China. Bull. World Health Organ. 79, 625–631 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Levine, M.M. et al. Duration of efficacy of Ty21a attenuated Salmonella typhi live oral vaccine. Vaccine 17, S22–S27 (1999).

    Article  PubMed  Google Scholar 

  70. Svennerholm, A.M. & Steele, D. Microbial-gut interactions in health and disease. Progress in enteric vaccine development. Best Pract. Res. Clin. Gastroenterol. 18, 421–445 (2004).

    Article  CAS  PubMed  Google Scholar 

  71. De Vos, B. et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr. Infect. Dis. J. 23, S179–S182 (2004).

    Article  PubMed  Google Scholar 

  72. Belshe, R., Lee, M.-S., Walker, R.E., Stoddard, J. & Mendelman, P.M. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev. Vaccines 3, 643–654 (2004).

    Article  CAS  PubMed  Google Scholar 

  73. Cox, R.J., Brokstad, K.A. & Ogra, P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59, 1–15 (2004).

    Article  CAS  PubMed  Google Scholar 

  74. Chaillous, L. et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Lancet 356, 545–549 (2000).

    Article  CAS  PubMed  Google Scholar 

  75. Wiendl, H. & Hohlfeld, R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16, 183–200 (2002).

    Article  CAS  PubMed  Google Scholar 

  76. Postlethwaite, A.E. Can we induce tolerance in rheumatoid arthritis? Curr. Rheumatol. Rep. 3, 64–69 (2001).

    Article  CAS  PubMed  Google Scholar 

  77. Sun, J.B., Rask, C., Olsson, T., Holmgren, J. & Czerkinsky, C. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc. Natl Acad. Sci. USA 93, 7196–7201 (1996).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Bergerot, I. et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc. Natl Acad. Sci. USA 94, 4610–4614 (1997).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Tarkowski, A., Sun, J.-B., Holmdahl, R., Holmgren, J. & Czerkinsky, C. Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine. Arthritis Rheum. 42, 1628–1634 (1999).

    Article  CAS  PubMed  Google Scholar 

  80. Phipps, P.A. et al. Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit. Eur. J. Immunol. 33, 224–232 (2003).

    Article  CAS  PubMed  Google Scholar 

  81. Tamura, S., Hatori, E., Tsuruhara, T., Aizawa, C. & Kurata, T. Suppression of delayed-type hypersensitivity and IgE antibody responses to ovalbumin by intranasal administration of Escherichia coli heat-labile enterotoxin B subunit-conjugated ovalbumin. Vaccine 15, 225–229 (1997).

    Article  CAS  PubMed  Google Scholar 

  82. Stanford, M. et al. Oral tolerization with peptide 336–351 linked to cholera toxin B subunit preventing relapses of uveitis in Behcet's disease. Clin. Exp. Immunol. 137, 201–208 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Wilson, D.R., Torres Lima, M. & Dirham, S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60, 4–12 (2005).

    Article  CAS  PubMed  Google Scholar 

  84. Di Rienzo, V. et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin. Exp. Allergy 33, 206–210 (2003).

    Article  CAS  PubMed  Google Scholar 

  85. Mastrandrea, F. The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis. Am. J. Clin. Dermatol. 5, 281–294 (2004).

    Article  PubMed  Google Scholar 

  86. Vrtala, S., Focke-Tejkl, M., Swoboda, I., Kraft, D. & Valenta, R. Strategies for converting allergens into hypoallergenic vaccine candidates. Methods 32, 313–320 (2004).

    Article  CAS  PubMed  Google Scholar 

  87. Holmgren, J., Czerkinsky, C., Eriksson, K. & Harandi, A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21, S89–S95 (2003).

    Article  PubMed  CAS  Google Scholar 

  88. Schoen, C., Stritzker, J., Goebel, W. & Pilgrim, S. Bacteria as DNA vaccine carriers for genetic immunization. Int. J. Med. Microbiol. 294, 319–335 (2004).

    Article  CAS  PubMed  Google Scholar 

  89. Vajdy, M. et al. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol. Cell Biol. 82, 617–627 (2004).

    Article  CAS  PubMed  Google Scholar 

  90. Shi, W., Liu, J., Huang, Y. & Qiao, L. Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T lymphocyte responses. J. Virol. 75, 10139–10148 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Guerrero, R.A. et al. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J. Virol. 75, 9713–9722 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Niikura, M. et al. Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology 293, 273–280 (2002).

    Article  CAS  PubMed  Google Scholar 

  93. Holmgren, J., Harandi, A.M. & Czerkinsky, C. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Expert Rev. Vaccines 2, 205–217 (2003).

    Article  CAS  PubMed  Google Scholar 

  94. Plant, A. & Williams, N.A. Modulation of the immune response by the cholera-like enterotoxins. Curr. Top. Med. Chem. 4, 509–519 (2004).

    Article  CAS  PubMed  Google Scholar 

  95. Pizza, M. et al. Mucosal vaccines: non-toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19, 2534–2541 (2001).

    Article  CAS  PubMed  Google Scholar 

  96. Lu, X., Clements, J.D. & Katz, J.M. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine 20, 1019–1029 (2002).

    Article  CAS  PubMed  Google Scholar 

  97. Sanchez, J., Wallerström, G., Fredriksson, M., Angstrom, J. & Holmgren, J. Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (STa-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants for vaccination. J. Biol. Chem. 277, 33369–33377 (2002).

    Article  CAS  PubMed  Google Scholar 

  98. Lycke, N. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM. Cell. Microbiol. 6, 23–32 (2004).

    Article  CAS  PubMed  Google Scholar 

  99. McCluskie, M.J., Weeratna, R.D., Payette, P.J. & Davis, H.L. The potential of CpG oligodeoxynucleotides as mucosal adjuvants. Crit. Rev. Immunol. 21, 103–120 (2001).

    CAS  PubMed  Google Scholar 

  100. Harandi, A.M. & Holmgren, J. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections. Curr. Opin. Investig. Drugs 5, 141–145 (2004).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Microbiology & Immunology and Göteborg University Vaccine Research Institute (GUVAX), Göteborg University, Göteborg, SE-405 30, Sweden

    Jan Holmgren

  2. INSERM Unité 721, Faculté de Médicine–Pasteur, Nice, F-06107, Cedex 02, France

    Cecil Czerkinsky

Authors
  1. Jan Holmgren
    View author publications

    Search author on:PubMed Google Scholar

  2. Cecil Czerkinsky
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Jan Holmgren.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holmgren, J., Czerkinsky, C. Mucosal immunity and vaccines. Nat Med 11 (Suppl 4), S45–S53 (2005). https://doi.org/10.1038/nm1213

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nm1213

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing